Zhitong Finance App learned that on May 27, according to the CDE clinical trial registration and information disclosure platform, Daiichi Sankyo/AstraZeneca (AZN.US) registered on the platform to launch a new phase III clinical tropion-lung14 study with osidinib to treat patients with locally advanced or metastatic NSCLC positive EGFR mutations (registration number: CTR20241813).

In addition, Daiichi Sankyo/AstraZeneca also registered to launch a phase III clinical tropion-lung15 study (registration number: NCT06417814) on the combination of dato-DXD and ositinib in the second-line treatment of EGFR mutant non-squamous NSCLC on the ClinicalTrials.gov platform. It is planned to enroll 630 subjects. It is expected that the enrollment of the first case will be completed in August this year.